Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
15 results
  • Prostate Cancer

20-656          Phase II

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression

  • Prostate Cancer

22-386          Phase II

A 2-stage, Lead-in and Randomized, Phase 2, Openlabel study of Darolutamide versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men with Hormone-Naïve Prostate Cancer (ARAMON)

  • Prostate Cancer

21-699          Phase I

A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer

  • Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Bladder Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Prostate Cancer

20-435          Phase I

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 as a Single Agent and in Combination with Second-Generation Anti-androgens in Patients with Advanced Prostate Cancer

  • Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Prostate Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

  • Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Gastric (Stomach) Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

  • Prostate Cancer

08-207          N/A

Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy

  • Prostate Cancer

19-267          N/A

Continuing Access to the Tyrosine Kinase Inhibitor Of VEGFR-2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials

Showing 1 - 10 of 15 results